Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
10 Apr 2024
10 Apr 2024
Historique:
received:
16
11
2023
accepted:
02
04
2024
medline:
11
4
2024
pubmed:
11
4
2024
entrez:
10
4
2024
Statut:
epublish
Résumé
Several studies have suggested the imprinting of SARS-CoV-2 immunity by original immune challenge without addressing the formation of the de novo response to successive antigen exposures. As this is crucial for the development of the original antigenic sin, we assessed the immune response against the mutated epitopes of omicron SARS-CoV-2 after vaccine breakthrough. Our data demonstrate a robust humoral response in thrice-vaccinated individuals following omicron breakthrough which is a recall of vaccine-induced memory. The humoral and memory B cell responses against the altered regions of the omicron surface proteins are impaired. The T cell responses to mutated epitopes of the omicron spike protein are present due to the high cross-reactivity of vaccine-induced T cells rather than the formation of a de novo response. Our findings, therefore, underpin the speculation that the imprinting of SARS-CoV-2 immunity by vaccination may lead to the development of original antigenic sin if future variants overcome the vaccine-induced immunity.
Identifiants
pubmed: 38600072
doi: 10.1038/s41467-024-47451-w
pii: 10.1038/s41467-024-47451-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3102Informations de copyright
© 2024. The Author(s).
Références
Sandmann, F. G. & Jit, M. Rapid COVID-19 vaccine rollout: immense success but challenges ahead. Lancet Infect. Dis. 22, 302–304 (2022).
pubmed: 34562376
doi: 10.1016/S1473-3099(21)00616-2
Mathieu, E. et al. Coronavirus pandemic (COVID-19), https://ourworldindata.org/coronavirus (2020).
Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021).
pubmed: 34182569
pmcid: 8935394
doi: 10.1038/s41586-021-03738-2
Walsh, E. E. et al. Safety and immunogenicity of Two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).
pubmed: 33053279
doi: 10.1056/NEJMoa2027906
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2020).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246
doi: 10.1056/NEJMoa2034577
Eyre, D. W. et al. Effect of covid-19 vaccination on transmission of alpha and delta Variants. N. Engl. J. Med. 386, 744–756 (2022).
pubmed: 34986294
doi: 10.1056/NEJMoa2116597
Prunas, O. et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 375, 1151–1154 (2022).
pubmed: 35084937
doi: 10.1126/science.abl4292
Macchia, A. et al. Evaluation of a COVID-19 vaccine campaign and SARS-CoV-2 infection and mortality among adults aged 60 years and older in a middle-income country. JAMA Netw. Open 4, e2130800–e2130800 (2021).
pubmed: 34714342
pmcid: 8556631
doi: 10.1001/jamanetworkopen.2021.30800
Pérez-Alós, L. et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat. Commun. 13, 1614 (2022).
pubmed: 35347129
pmcid: 8960902
doi: 10.1038/s41467-022-29225-4
Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).
pubmed: 34614326
doi: 10.1056/NEJMoa2114583
Monzon-Posadas, W. O. et al. Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2. Front. Immunol. 14, 1066123 (2023).
pubmed: 36742295
pmcid: 9893859
doi: 10.3389/fimmu.2023.1066123
Wang, S. Y. et al. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. Lancet Microbe 3, e4–e5 (2022).
pubmed: 34901896
doi: 10.1016/S2666-5247(21)00306-2
Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med 385, 1474–1484 (2021).
pubmed: 34320281
doi: 10.1056/NEJMoa2109072
Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).
pubmed: 32087114
pmcid: 7159018
doi: 10.1016/S1473-3099(20)30120-1
Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161–1179 (2022).
pubmed: 35798890
pmcid: 9352574
doi: 10.1038/s41564-022-01143-7
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
pubmed: 35016194
doi: 10.1038/s41586-021-04385-3
Pušnik, J. et al. SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection. Nat. Commun. 14, 572 (2023).
pubmed: 36732523
pmcid: 9894521
doi: 10.1038/s41467-023-36250-4
Szekely, J. et al. Breakthrough SARS-CoV-2 Omicron variant in individuals primed with heterologous vaccines enhances inhibition performance of neutralizing antibody to BA.2 parental lineage. Vaccines (Basel) 11, 1230 (2023).
pubmed: 37515045
doi: 10.3390/vaccines11071230
Muik, A. et al. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5. Sci. Immunol. 7, eade2283 (2022).
pubmed: 36125366
doi: 10.1126/sciimmunol.ade2283
Lee, W. S. et al. Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection. Sci. Adv. 9, eadg5301 (2023).
pubmed: 37478181
pmcid: 10361595
doi: 10.1126/sciadv.adg5301
Zhang, A., Stacey, H. D., Mullarkey, C. E. & Miller, M. S. Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses. J. Immunol. 202, 335–340 (2019).
pubmed: 30617114
doi: 10.4049/jimmunol.1801149
Roncati, L. & Palmieri, B. What about the original antigenic sin of the humans versus SARS-CoV-2? Med Hypotheses 142, 109824 (2020).
pubmed: 32408068
pmcid: 7204740
doi: 10.1016/j.mehy.2020.109824
Kohler, H. & Nara, P. A novel hypothesis for original antigenic sin in the severe disease of SARS-CoV-2 infection. Monoclon. Antib. Immunodiagn. Immunother. 39, 107–111 (2020).
pubmed: 32762609
doi: 10.1089/mab.2020.0029
Aydillo, T. et al. Immunological imprinting of the antibody response in COVID-19 patients. Nat. Commun. 12, 3781 (2021).
pubmed: 34145263
pmcid: 8213790
doi: 10.1038/s41467-021-23977-1
Aguilar-Bretones, M. et al. Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. J. Clin. Invest 131, e150613 (2021).
pubmed: 34499051
pmcid: 8553556
doi: 10.1172/JCI150613
Dowell, A. C. et al. Immunological imprinting of humoral immunity to SARS-CoV-2 in children. Nat. Commun. 14, 3845 (2023).
pubmed: 37386081
pmcid: 10310754
doi: 10.1038/s41467-023-39575-2
Röltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025–1040.e1014 (2022).
pubmed: 35148837
pmcid: 8786601
doi: 10.1016/j.cell.2022.01.018
Park, Y.-J. et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 378, 619–627 (2022).
pubmed: 36264829
doi: 10.1126/science.adc9127
Ju, B. et al. Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections. Nat. Commun. 13, 7120 (2022).
pubmed: 36402756
pmcid: 9675777
doi: 10.1038/s41467-022-34400-8
Pérez-Alós, L. et al. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk. Nat. Commun. 14, 5624 (2023).
pubmed: 37699890
pmcid: 10497567
doi: 10.1038/s41467-023-41342-2
Reynolds, C. J. et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 377, eabq1841 (2022).
pubmed: 35699621
doi: 10.1126/science.abq1841
Collier, A. Y. et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N. Engl. J. Med. 388, 565–567 (2023).
pubmed: 36630611
doi: 10.1056/NEJMc2213948
Wang, Q. et al. Antibody response to Omicron BA.4–BA.5 bivalent booster. N. Engl. J. Med. 388, 567–569 (2023).
pubmed: 36630643
doi: 10.1056/NEJMc2213907
Solforosi, L. et al. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques. Nat. Commun. 14, 1944 (2023).
pubmed: 37029141
pmcid: 10080532
doi: 10.1038/s41467-023-37715-2
Regev-Yochay, G. et al. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe 4, e309–e318 (2023).
pubmed: 36963419
pmcid: 10030121
doi: 10.1016/S2666-5247(23)00012-5
Gilbert, P. B. et al. A Covid-19 milestone attained—a correlate of protection for vaccines. N. Engl. J. Med. 387, 2203–2206 (2022).
pubmed: 36507702
doi: 10.1056/NEJMp2211314
Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040 (2021).
pubmed: 34588689
pmcid: 8604724
doi: 10.1038/s41591-021-01540-1
Zhao, Z. et al. Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape. Nat. Commun. 13, 4958 (2022).
pubmed: 36002453
pmcid: 9399999
doi: 10.1038/s41467-022-32665-7
Wu, L. et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. Signal Transduct. Target. Ther. 7, 8 (2022).
pubmed: 34987150
pmcid: 8727475
doi: 10.1038/s41392-021-00863-2
Morales-Núñez, J. J., Muñoz-Valle, J. F., Torres-Hernández, P. C. & Hernández-Bello, J. Overview of neutralizing antibodies and their potential in COVID-19. Vaccines (Basel) 9, 1376 (2021).
pubmed: 34960121
doi: 10.3390/vaccines9121376
Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186–193 (2022).
pubmed: 35105982
doi: 10.1038/s41590-021-01122-w
Kundu, R. et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat. Commun. 13, 80 (2022).
pubmed: 35013199
pmcid: 8748880
doi: 10.1038/s41467-021-27674-x
Noori, M., Nejadghaderi, S. A. & Rezaei, N. “Original antigenic sin”: a potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants. Infect. Control Hosp. Epidemiol. 43, 1091–1092 (2022).
pubmed: 33938416
doi: 10.1017/ice.2021.199
Rijkers, G. T. & van Overveld, F. J. The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination. Clinical Immunology Communications. https://doi.org/10.1016/j.clicom.2021.10.001 (2021).
Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339–1343 (2020).
pubmed: 33159009
pmcid: 7857411
doi: 10.1126/science.abe1107
Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 370, eabd4250 (2020).
pubmed: 32994364
pmcid: 7857405
doi: 10.1126/science.abd4250
Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).
pubmed: 35016195
doi: 10.1038/s41586-021-04386-2
Hornsby, H. et al. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nat. Commun. 14, 5065 (2023).
pubmed: 37604803
pmcid: 10442364
doi: 10.1038/s41467-023-40592-4
Loyal, L. et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science 374, eabh1823 (2021).
pubmed: 34465633
pmcid: 10026850
doi: 10.1126/science.abh1823
Liu, J. et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 603, 493–496 (2022).
pubmed: 35102312
pmcid: 8930761
doi: 10.1038/s41586-022-04465-y
Aguilar-Bretones, M., Fouchier, R. A. M., Koopmans, M. P. G. & van Nierop, G. P. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. The Journal of Clinical Investigation 133, https://doi.org/10.1172/JCI162192 (2023).
Zhou, Z., Barrett, J. & He, X. Immune Imprinting and Implications for COVID-19. Vaccines (Basel) 11, https://doi.org/10.3390/vaccines11040875 (2023).